BPC-157 TB-500 FAQ: the questions people actually ask, answered from the studies.

Frequently asked questions about the BPC-157 TB-500 (Wolverine) blend

Short, cited answers to the most common BPC-157 TB-500 questions. Where an answer makes a quantitative claim, it points to a numbered study in the full reference list.

Is there any study showing BPC-157 and TB-500 work better together (synergy)?

No. No peer-reviewed study has defined a synergy ratio, dose, or endpoint for the two peptides given together. A 2025 systematic review of BPC-157 in orthopaedic sports medicine (36 studies, only 1 human, "no clinical safety data") makes no mention of TB-500 or any combination ^[8]. "Synergy" is extrapolated from each peptide's separately characterized, largely non-overlapping mechanism, not demonstrated in a controlled combination study.

What are the side effects of BPC-157 and TB-500?

The assembled blend has no controlled human safety data. Component human data are limited, and a 2026 Sports Medicine review cautions that rigorous human safety data for unapproved musculoskeletal peptides are scarce, with potential for serious harm ^[9]. The principal theoretical concern is the pro-angiogenic and pro-migratory tumor signal associated with Thymosin Beta-4, which compounds when two pro-repair peptides are combined ^[5].

Does TB-500 cause cancer or promote tumor growth?

Thymosin Beta-4 has been implicated in tumor metastasis and angiogenesis — the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression, a concern that compounds when two pro-repair peptides are combined ^[5]. This is a recognized safety signal, not a demonstrated effect of the blend; no carcinogenicity data exist for the combination.

Is the BPC-157 / TB-500 blend safe for long-term use?

Long-term safety of the blend is unknown. There are no controlled long-term human studies of the combination, BPC-157's long-term human safety is unestablished (only three small pilot studies exist) ^[10], and the Thymosin Beta-4 tumor-angiogenesis signal is a standing theoretical concern ^[5]. Both constituents are unapproved and WADA-prohibited; long-term use cannot be characterized as safe from the published evidence.

What do doctors and reviews say about the BPC-157 + TB-500 blend?

Recent peer-reviewed reviews are cautious: they describe preclinical promise for the constituents but emphasize that human data are extremely limited, that BPC-157 should be considered investigational given regulatory controversy and non-regulated availability ^[10], and that rigorous human safety data for unapproved musculoskeletal peptides are scarce with potential for serious harm ^[9].

What is the Wolverine peptide blend?

Wolverine is a research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair "stack." It is not a single chemical entity, has no single molecular weight or CAS number, and is not an approved product anywhere ^[9].

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region (residues 17-23) of Thymosin Beta-4 ^[3]. The Wolverine blend pairs the two as a research-community tissue-repair "stack"; it is not a single chemical entity or an approved product ^[9].

What is the BPC-157 and TB-500 blend used for in research?

Its two components occupy complementary nodes of a tissue-repair network in preclinical work: BPC-157 for cytoprotection, angiogenesis, and tendon/ligament repair in rodent models ^[1][2], and TB-500 / Thymosin Beta-4 for cell migration, re-epithelialization, and wound healing in animal and biochemical models ^[3][4]. The assembled blend itself has not been tested in a controlled study ^[8].

Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The rationale is complementary mechanisms: BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS), while TB-500 / Thymosin Beta-4 supplies an intracellular actin-sequestration signal (1:1 G-actin binding via LKKTETQ) ^[2][3]. The two are described as acting through complementary but largely non-overlapping pathways — the basis of the "synergy" claim, which remains a theoretical extrapolation ^[8].

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is approved by the FDA for human use, and the blend has no approved therapeutic indication. FDA placed both BPC-157 and the "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" entry in 503A Category 2 effective September 29, 2023, and both are on the July 2026 PCAC review agenda ^[11][12]. Both constituents are prohibited by WADA — BPC-157 under S0, and TB-500 / Thymosin Beta-4 under prohibited peptide and growth-factor categories.

Are there human clinical trials on the BPC-157 + TB-500 combination?

There are no controlled clinical trials of the combination for any indication. Human data exist only for the individual constituents and are themselves thin: BPC-157 has three small pilot studies ^[10], and "TB-500" human data are for full-length Thymosin Beta-4 (Phase 1 IV studies), not the heptapeptide ^[7]. The blend's human efficacy and combination safety are unproven.

Does the BPC-157 TB-500 blend help tendon and ligament injuries?

The tendon/ligament evidence is preclinical and single-compound. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures ^[1], and Thymosin Beta-4 (TB-500's parent) supports cell migration and angiogenesis relevant to soft-tissue repair ^[4]. No controlled study has tested the combined blend in tendon or ligament injury ^[8].

Does BPC-157 and TB-500 help muscle tears and recovery?

Muscle-repair signals are preclinical and single-compound. A notable counter-result tempers the recovery narrative: in dystrophin-deficient mdx mice, chronic Thymosin Beta-4 increased the number of regenerating skeletal-muscle fibers but did NOT improve muscle strength, cardiac function, or fibrosis ^[6]. No combination muscle-recovery trial exists ^[8].

How does TB-500 work (actin / Thymosin Beta-4)?

TB-500's LKKTETQ motif binds monomeric G-actin one-to-one and sequesters it, regulating the cytoskeletal dynamics that drive cell migration and re-epithelialization. X-ray crystallography of a gelsolin-domain-Thymosin Beta-4 hybrid bound to actin established this 1:1 dual-end-capping mechanism ^[3]. Note: most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4, not the 7-mer ^[7].

How does BPC-157 work compared to TB-500?

BPC-157 works through a cytoprotective and angiogenic route — up-regulating VEGFR2 with downstream Akt-eNOS signaling and modulating the nitric-oxide system ^[2] — while TB-500 works through actin sequestration that regulates cell migration ^[3]. They are described as complementary but largely non-overlapping mechanisms, which is the rationale for pairing them in the blend.

What is the half-life of BPC-157 and TB-500?

No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study. Human IV full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide ^[7].

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid pentadecapeptide derived from a gastric-juice protein, acting through VEGFR2-driven angiogenesis and cytoprotection ^[2]. TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ) of Thymosin Beta-4, acting through G-actin sequestration that regulates cell migration ^[3]. They differ in size, origin, and primary mechanism, which is why they are paired as complementary repair signals.

Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?

Both promote angiogenesis by distinct routes in preclinical models. BPC-157 up-regulates VEGFR2 and promotes its internalization, with downstream VEGFR2-Akt-eNOS signaling, increasing vessel density and blood-flow recovery in ischemic muscle ^[2]. Thymosin Beta-4 (TB-500's parent) promotes endothelial migration and angiogenesis as part of its consolidated regenerative mechanism ^[4].

Does the BPC-157 TB-500 blend help wound healing?

Wound-healing evidence is single-compound and preclinical. Thymosin Beta-4 (TB-500's parent) is reported to decrease myofibroblast number (reducing scar formation), limit apoptosis and inflammation after injury, and promote angiogenesis and cell migration ^[4]; BPC-157 contributes cytoprotective and angiogenic signals ^[2]. The assembled blend has not been tested for wound healing in a controlled study ^[8].

Is Wolverine legal?

"Wolverine" is a nickname for a blend of two peptides, and neither is an FDA-approved drug; the blend has no approved therapeutic indication. Both components are in FDA's 503A Category 2 today, so they are not eligible for routine 503A compounding while that status stands ^[11], and both are WADA-prohibited in sport. Both are also under scheduled FDA review for July 2026, so the access picture is being actively reconsidered ^[12]. This is general regulatory information, not legal advice.

Can you get BPC-157 from a compounding pharmacy?

Currently, BPC-157 is in FDA's 503A Category 2 — identified as a bulk drug substance that may present significant safety risks and not covered by FDA's enforcement-discretion policy for 503A compounding ^[11][13]. While that status stands, it is not eligible for routine 503A compounding. BPC-157 is on the July 23-24, 2026 PCAC agenda as a substance under evaluation for the 503A Bulks List, which is a scheduled review, not a decision ^[12].

What is the FDA 503A status of Wolverine?

Both of Wolverine's components sit in FDA's 503A Category 2. FDA placed BPC-157, and separately "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500," in Category 2 effective with the September 29, 2023 update to the nominated-substances list, identifying them as bulk drug substances that may present significant safety risks ^[11]. Category 2 substances are not covered by FDA's enforcement-discretion policy for 503A compounding ^[13].